Abstract
Purpose of Review: To provide an overview and highlight recent updates in the field of paraneoplastic neurologic disorders. Recent Findings: The prevalence of paraneoplastic neurologic disorders is greater than previously reported and the incidence has been rising over time, due to improved recognition in the era of antibody biomarkers. Updated diagnostic criteria that are broadly inclusive and also contain diagnostic risk for clinical presentations (high and intermediate) and diagnostic antibodies (high, intermediate, and low) have replaced the original 2004 criteria. Antibody biomarkers continue to be characterized (e.g., KLHL-11 associated with seminoma in men with brainstem encephalitis). Some paraneoplastic antibodies also provide insight into likely immunotherapy response and prognosis. The rise of immune checkpoint inhibitors as cancer therapeutics has been associated with newly observed immune-mediated adverse effects including paraneoplastic neurological disorders. The therapeutic approach to paraneoplastic neurologic disorders is centered around cancer care and trials of immune therapy. Summary: The field of paraneoplastic neurologic disorders continues to be advanced by the identification of novel antibody biomarkers which have diagnostic utility, and give insight into likely treatment responses and outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 67-82 |
| Number of pages | 16 |
| Journal | Current neurology and neuroscience reports |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
Keywords
- Autoimmune neurology
- Diagnostic criteria
- Immune checkpoint inhibitors
- Paraneoplastic neurologic syndromes
ASJC Scopus subject areas
- General Neuroscience
- Clinical Neurology